瑞舒伐他汀联合替格瑞洛对急性心肌梗死患者疗效、心功能及炎症因子水平的影响

Influence of rosuvastatin combined ticagrelor on therapeutic effect,cardiac function and inflammatory factor levels in patients with acute myocardial infarction

目的:探讨瑞舒伐他汀联合替格瑞洛对急性心肌梗死(AMI)患者疗效、心功能及炎症因子水平的影响。方法:选择我院收治的288例AMI患者,随机分为瑞舒伐他汀组(144例,采用瑞舒伐他汀治疗)与联合治疗组(144例,采用瑞舒伐他汀联合替格瑞洛治疗),治疗2个月后,比较两组疗效、心功能、炎症指标水平及不良反应发生率。结果:联合治疗组的总有效率显著高于瑞舒伐他汀组(96.53%比86.81%,P=0.003)。与治疗前比较,治疗后两组心功能、炎症因子水平均有显著改善(P均=0.001);与瑞舒伐他汀组比较,联合治疗组左室舒张末期内径(LVEDd)[(44.86±5.25)mm比(30.94±4.02)mm]、左室收缩末期内径(LVESd)[(28.83±3.02)mm比(21.27±2.86)mm]、室间隔厚度(IVST)[(9.82±1.51)mm比(9.09±1.46)mm]均显著减小,白细胞介素-6(IL-6)[(4.62±0.68)pg/ml比(3.85±0.59)pg/ml]及肿瘤坏死因子α(TNF-α)[(1.25±0.22)pg/ml比(0.93±0.18)pg/ml]水平均显著降低,6 min步行距离(6MWD)[(398.63±50.58)m比(436.35±52.03)m]和左心室射血分数(LVEF)[(54.11±6.32)%比(60.24±7.88)%]显著增加(P均=0.001)。两组在治疗期间不良反应总发生率无显著差异(P=0.444)。结论:瑞舒伐他汀联合替格瑞洛治疗AMI患者效果显著,可改善患者的心功能,降低炎症因子水平,且安全性好。

Objective:To investigate the influence of rosuvastatin combined ticagrelor on therapeutic effect,cardiac function and inflammatory factor levels in patients with acute myocardial infarction(AMI).Methods:A total of 288 AMI patients admitted in our hospital were randomly and equally divided into rosuvastatin group(received rosuvastatin therapy)and combined treatment group(received rosuvastatin combined with ticagrelor).After two-month treatment,therapeuticeffect,cardiac function,inflammatory index levels and incidence rate of adverse reaction were compared between two groups.Results:Total effective rate of combined treatment group was significantly higher than that of rosuvastatin group(96.53%vs.86.81%,P=0.003).Compared with before treatment,there were significant improvements in cardiac function and inflammatory factor levels in two groups after treatment,P=0.001 all.Compared with rosuvastatin group after treatment,there were significant reductions in left ventricular end-diastolic diameter(LVEDd)[(44.86±5.25)mmvs.(30.94±4.02)mm],left ventricular end-systolic diameter(LVESd)[(28.83±3.02)mmvs.(21.27±2.86)mm],interventricular septal thickness(IVST)[(9.82±1.51)mmvs.(9.09±1.46)mm],levels of interleukin-6(IL-6)[(4.62±0.68)pg/mlvs.(3.85±0.59)pg/ml]and tumor necrosis factor-α(TNF-α)[(1.25±0.22)pg/mlvs.(0.93±0.18)pg/ml],and significant rise in 6 min walking distance(6MWD)[(398.63±50.58)m vs.(436.35±52.03)m]and LVEF[(54.11±6.32)%vs.(60.24±7.88)%]in combined treatment group,P=0.001 all.There was no significant difference in total incidence rate of adverse reactions during treatment between two groups,P=0.444.Conclusion:The combination of rosuvastatin and ticagrelor possesses significant therapeutic effect in the treatment of AMI patients.It can improve cardiac function and reduce levels of inflammatory factors with good safety.